Dr. Welslau on the Rationale for Rituximab Biosimilar Combination in DLBCL
June 29th 2020Manfred Welslau, MD, discusses the rationale for investigating the Sandoz rituximab biosimilar, Rixathon, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.
Read More
Dr. Welslau on Acceptance of Rituximab Biosimilar in DLBCL
August 28th 2019Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses the growing acceptance of a rituximab (Rituxan) biosimilar in the treatment of patients with diffuse large B-cell lymphoma, following favorable results from a safety analysis of the REFLECT study.
Read More